Product Spotlight: Invokana® (canagliflozin)
Janssen Pharmaceuticals, Inc.’s Invokana® (canagliflozin) was approved by the FDA on March 29, 2013, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is not recommended for the treatment of type 1 diabetes or diabetic ketoacidosis. Canagliflozin was the first diabetes treatment approved in the class of drugs known as sodium-glucose cotransporter-2 inhibitors.
This First Report Managed Care Product Spotlight highlights 6 of the phase 3 trials that evaluated the safety and effectiveness of canagliflozin. These include canagliflozin as monotherapy; canagliflozin compared with the dipeptidyl peptidase-4 inhibitor sitagliptin and a sulfonylurea (glimepiride); and canagliflozin in older adults and in patients with moderate renal impairment.
